Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 57Kidney Neoplasms 16Neoplasms 15Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Colorectal Neoplasms 8Carcinoma, Hepatocellular 8Melanoma 7Carcinoma 6Glioblastoma 5Clear-cell metastatic renal cell carcinoma 5Lung Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Ovarian Neoplasms 3Endometrial Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Sarcoma 2Pheochromocytoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Paraganglioma 2Liver Neoplasms 2Kidney Diseases 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2cT2a N0NxM0 Renal Tumor 1

Interventions

Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Refractory or Recurrent Solid Tumors, Excluding CNS Tumors × Axitinib × Clear all
NCT02164838 2018-01-29

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
51 enrolled
Other solid neoplasm

Refractory or Recurrent Solid Tumors, Excluding CNS Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡